## Supplementary material

## Table S1. Details of the NP, AK-RSA and URSA patients (\*\* P < 0.01, \*\*\* P

| Parameters   | NP              | AK-RSA          | URSA            |                   | P Value        |                   |
|--------------|-----------------|-----------------|-----------------|-------------------|----------------|-------------------|
| Maternal age | 31.04 ± 0.8220, | 32.19 ± 0.5494, | 30.35 ± 0.9812, | NP vs URSA        | AK-RSA vs URSA | NP vs AK-RSA      |
| (y)          | n=24            | n=16            | n=17            | P =0.05933        | P=0.1189       | P =0.3063         |
| Gestation    | 6.58 ± 0.2030,  | 6.73 ± 0.4179,  | 6.60 ± 0.3748,  | NP vs URSA        | AK-RSA vs URSA | NP vs AK-RSA      |
| age (weeks)  | n=24            | n=16            | n=17            | <i>P</i> =0.9615  | P =0.8104      | <i>P</i> =0.7152  |
| Number of    | $0.0 \pm 0.0,$  | 1.44 ± 0.1281,  | 2.65 ± 0.2090,  | NP vs URSA        | AK-RSA vs URSA | NP vs AK-RSA      |
| miscarriage  | n=24            | n=16            | n=17            | <i>P</i> < 0.0001 | P < 0.0001     | <i>P</i> < 0.0001 |
| Number of    | 1.33 ± 0.0982,  | 0.06 ± 0.0625,  | 0.35 ± 0.2090,  | NP vs URSA        | AK-RSA vs URSA | NP vs AK-RSA      |
| live births  | n=24            | n=16            | n=17            | <i>P</i> < 0.0001 | P =0.2043      | <i>P</i> < 0.0001 |
| Number of    | 3.04 ± 0.2039,  | 1.62 ± 0.1797,  | 3.056 ± 0.2775, | NP vs URSA        | AK-RSA vs URSA | NP vs AK-RSA      |
| pregnancies  | n=24            | n=16            | n=17            | P =0.9596         | P < 0.0001     | <i>P</i> < 0.0001 |

< 0.001, \*\*\*\* *P* < 0.0001, NS, not significant).



Figure S1. The secretion of IFN- $\gamma$  and VEGF $\alpha$  by dNK cells from URSA donors decreased and was positively correlated with the levels of HLA-E in T-EVs.

**A. B.** dNK cells were purified from decidual tissues from NP, AK-RSA or URSA patients and seeded into 96-well plates at  $1 \times 10^5$  cells/well in complete medium containing 50 ng/ml IL-15 for 48 h. Intracellular expression of IFN- $\gamma$ and VEGF $\alpha$  in CD3<sup>-</sup>CD56<sup>+</sup> dNK cells obtained from NP, AK-RSA or RSA patients was detected by FCM. **C.** The expression of NKG2C in CD3<sup>-</sup>CD56<sup>+</sup> dNK cells obtained from NP, AK-RSA or RSA patients was detected by FCM and statistically analyzed. **D.** Intracellular expression of IFN- $\gamma$  and VEGF $\alpha$  in CD3<sup>-</sup>CD56<sup>+</sup> dNK cells obtained from NP, AK-RSA or RSA patients was statistically analyzed. **E.** Supernatants of the dNK cells in **B.** were evaluated by ELISA, and the results were statistically analyzed. **F.** The correlations between the HLA-E level in T-EVs and intracellular IFN- $\gamma$  and VEGF $\alpha$ expression in dNK cells were analyzed by Spearman correlation analysis using GraphPad Prism 6 (n=11). P values were generated by one-way analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test using GraphPad Prism 6 (n=11 in NP group; n=11 in AK-RSA patient group; n=8 in URSA patient group, \**P* < 0.05, \*\* *P* < 0.01, \*\*\*\* *P* < 0.001, \*\*\*\* *P* < 0.0001, NS, not significant).



Figure S2. Exosomes from JEG-3 cells promote the secretion of IFN-y

## and VEGF $\alpha$ by dNK cells via HLA-E in vitro.

**A.** Western blot analysis of HLA-E, Alix, GRP94, TSG101 and CD9 in exosomes and cell lysates derived from negative control siRNA-treated JEG-3 cells (siNC-JEG-3) and HLA-E-specific siRNA-treated JEG-3 cells (siHLA-E-JEG-3). **B.** The intracellular expression of IFN-γ and VEGFα in dNK cells from URSA patients was detected by FCM and **C.** statistically analyzed. P values were generated by one-way analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test using GraphPad Prism 6 (n=7, \**P* < 0.05; \*\**P* <0.01; \*\*\* *P* < 0.001; \*\*\*\* *P* < 0.0001; NS, not significant).



## Figure S3. The secretion of IFN- $\gamma$ and VEGF $\alpha$ by dNK cells from NP donors was dependent on cellular metabolism.

**A.** Intracellular expression of IFN-γ and VEGFα in dNK cells from NP donors treated with or without the glycolytic inhibitor 2-DG (1 mM) or ATP synthase inhibitor oligomycin (20 µM) was detected by FCM and statistically analyzed in **B. C.** Supernatants of the dNK cells in **a.** were detected by ELISA, and the results were statistically analyzed. **D.** Intracellular staining for pS6, IFN-γ and VEGFα in dNK cells treated with 10 nM mTORC1 inhibitor (rapamycin) was evaluated by FCM and statistically analyzed in **E. F.** Supernatants of the dNK cells in **D** were detected by ELISA, and the results were statistically analyzed in **E. F.** Supernatants of the dNK cells in **D** were detected by ELISA, and the results were statistically analyzed. The data are representative of three independent experiments or are shown as the mean±s.e.m. pooled from three independent experiments. P values were generated by one-way analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test using GraphPad Prism 6 (n=14, \**P* < 0.005; \*\* *P* < 0.01; \*\*\* *P* < 0.001; \*\*\*\* *P* < 0.0001; NS, not significant).